Another boost is coming to the BioHealth Capital Region’s growing biomanufacturing ecosystem.
Frederick-based BioFactura, a clinical-stage biopharma company known for its biosimilars and biodefense work, has launched Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division designed to help startups and government partners move biologics from concept to clinic.
Capitol Biologics will focus on early-phase clinical manufacturing and process development — offering cell line development, upstream and downstream optimization, GMP manufacturing, and full analytical support under globally aligned quality standards.
A Homegrown Solution for Emerging Biotechs
For BioFactura, this move builds on two decades of biologics development experience and answers a growing need for phase-appropriate CDMO support in the region.
“Transforming the biopharma development engine that BioFactura has built over the past 20 years into a pure-play service organization provides an incomparable value to early-stage ventures and initiatives,” said Darryl Sampey, BioFactura’s president and CEO. “The depth of experience and capability that we’ve gained saves our clients both time and money — resources that are often existential to their survival and success.”
Dr. Jeffrey Hausfeld, chairman of the board and chief medical officer, framed the launch as the “next evolution” of the company’s mission. “We are combining our proven technical excellence with a collaborative service model to help innovators advance their therapies faster, more efficiently, and with the highest quality standards,” he said.
Fit for Purpose, Right in Frederick
Located in the I-270 Biotech Corridor, Capitol Biologics is strategically positioned to support biotech startups, government agencies, and public health initiatives. Its team emphasizes being “fit for purpose” — delivering what clients need, when they need it — with a culture of problem-solving and entrepreneurship.
“Our mission is to get our clients from concept to clinic… seamlessly,” the company stated.
Why It Matters
For the BioHealth Capital Region, Capitol Biologics adds critical infrastructure at a time when demand for biologics manufacturing is surging. From supporting emerging biotech innovators to bolstering national biodefense preparedness, the new division strengthens the region’s position as a hub for advanced biologics development and manufacturing.
